|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 23.55 USD | -4.23% |
|
-2.65% | +75.88% |
| 18/05 | Trump's psychedelic drug order boosts investor interest with promise of faster reviews | RE |
| 12/05 | Definium Therapeutics Begins Patient Dosing in Ascend Phase 3 Depression Trial | MT |
| Capitalization | 256.85Cr 222.43Cr 204.1Cr 192.02Cr 357.65Cr 24TCr 363.24Cr 2.43TCr 944.15Cr 12TCr 964.43Cr 943.44Cr 41TCr | P/E ratio 2026 * |
-10.4x | P/E ratio 2027 * | -14.2x |
|---|---|---|---|---|---|
| Enterprise value | 215.01Cr 186.2Cr 170.85Cr 160.74Cr 299.39Cr 20TCr 304.07Cr 2.03TCr 790.35Cr 9.91TCr 807.33Cr 789.76Cr 34TCr | EV / Sales 2026 * |
-
| EV / Sales 2027 * | 86.3x |
| Free-Float |
99.05% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Definium Therapeutics, Inc.
| 1 day | -4.23% | ||
| 1 week | -2.65% | ||
| Current month | -2.65% | ||
| 1 month | +0.56% | ||
| 3 months | +33.35% | ||
| 6 months | +90.69% | ||
| Current year | +75.88% |
| 1 week | 22.15 |  | 25.16 |
| 1 month | 19.33 | | 25.16 |
| Current year | 12.88 | | 26.25 |
| 1 year | 6.34 | | 26.25 |
| 3 years | 2.41 | | 26.25 |
| 5 years | 2.12 | | 60.6 |
| 10 years | 1.25 | | 86.55 |
| Manager | Title | Age | Since |
|---|---|---|---|
Robert Barrow
CEO | Chief Executive Officer | 37 | 09/06/2021 |
Brandi Roberts
DFI | Director of Finance/CFO | 52 | 02/06/2025 |
Daniel Karlin
CTO | Chief Tech/Sci/R&D Officer | 46 | 01/02/2021 |
| Director | Title | Age | Since |
|---|---|---|---|
Robert Barrow
BRD | Director/Board Member | 37 | 13/12/2021 |
Andreas Krebs
BRD | Director/Board Member | 67 | 29/09/2021 |
Carol Vallone
CHM | Chairman | 69 | 13/12/2021 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 25/03 | Sell | General Counsel | 10,702 | 0.0109% | ||
| 25/03 | Sell | Chief Executive Officer | 24,431 | 0.0248% | ||
| 25/03 | Sell | Chief Technology Officer | 8,018 | 0.0081% |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -4.23% | -2.65% | +202.31% | +557.82% | 256.85Cr | |
| -1.18% | -2.96% | -15.31% | -18.77% | 4.27TCr | |
| -4.15% | -5.24% | +263.18% | +452.70% | 3.17TCr | |
| -1.84% | +0.68% | +20.44% | -10.72% | 3.06TCr | |
| -3.51% | -6.19% | +5.57% | +19.44% | 3TCr | |
| -2.89% | -6.70% | +14.76% | +14.13% | 2.42TCr | |
| -0.18% | +3.94% | +11.24% | +4.51% | 1.32TCr | |
| -3.83% | -6.10% | - | - | 1.31TCr | |
| -0.97% | +1.60% | +53.20% | +106.80% | 1.3TCr | |
| -0.87% | -2.64% | +111.05% | +71.89% | 1.23TCr | |
| Average | -2.36% | -2.63% | +74.05% | +133.09% | 2.13TCr | |
| Weighted average by Cap. | -2.35% | -3.12% | +57.77% | +89.47% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | - | 2.63Cr 2.28Cr 2.09Cr 1.97Cr 3.67Cr 250.95Cr 3.72Cr 25Cr 9.68Cr 121.36Cr 9.89Cr 9.67Cr 422.04Cr |
| Net income | -25Cr -22Cr -20Cr -19Cr -35Cr -2.43TCr -36Cr -240.65Cr -94Cr -1.17TCr -96Cr -94Cr -4.08TCr | -21Cr -19Cr -17Cr -16Cr -30Cr -2.04TCr -30Cr -201.99Cr -79Cr -985.55Cr -80Cr -79Cr -3.43TCr |
| Net Debt | -42Cr -36Cr -33Cr -31Cr -58Cr -3.99TCr -59Cr -395.18Cr -153.8Cr -1.93TCr -157.1Cr -153.68Cr -6.71TCr | -30Cr -26Cr -23Cr -22Cr -41Cr -2.81TCr -42Cr -278.63Cr -108.44Cr -1.36TCr -110.77Cr -108.36Cr -4.73TCr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 05/26/05 | 23.55 $ | -4.23% | 41,82,244 |
| 04/26/04 | 24.59 $ | +4.24% | 25,64,327 |
| 03/26/03 | 23.59 $ | +3.19% | 22,93,669 |
| 02/26/02 | 22.86 $ | -4.99% | 22,86,589 |
| 01/26/01 | 24.06 $ | -0.54% | 17,36,076 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- DFTX Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition